FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040996502> ?p ?o ?g. }

• W2040996502 endingPage "2775" @default.
• W2040996502 startingPage "2768" @default.
• W2040996502 abstract "One hundred and three acromegalic patients from 14 medical centers were enrolled in this study to determine the efficacy and safety of the somatostatin analog, octreotide acetate, during long term treatment. Seventy percent of the patients had undergone previous surgery or radiation treatment. Octreotide was initiated at a dose of 100 micrograms, sc, every 8 h and gradually increased to a maximum of 1500 micrograms daily depending upon the individual patient's clinical and biochemical response [GH and insulin-like growth factor I (IGF-I) reduction]. The mean duration of treatment was 24 months (range, 3-30 months). However, most patients were treated for a mean of 30 months, because this study took place after an initial 6-month study previously reported. Mean serum GH fell from 30.9 micrograms/L (range, 2.7-350) to 5.7 micrograms/L (range, 0.6-59) at the 3 months visit and remained suppressed (P < 0.001). Plasma IGF-I concentrations were also significantly reduced and remained in the normal range for at least half of the treatment visits in 56 of 87 patients (64%) treated for 12-30 months. Patients with higher initial GH concentrations were less likely to normalize IGF-I concentrations during treatment (P < 0.001). There was no evidence of drug tachyphylaxis in those patients who continued taking stable doses of medication. With some exceptions, dose increments above 800 micrograms daily in 31 patients did not provide additional benefit in terms of GH and IGF-I reduction. Headache, excessive perspiration, fatigue, and joint pain were ameliorated in 83-95% of patients. Mean finger circumference was decreased significantly at the 12 month visit (P < 0.05). The most common adverse events reported were diarrhea, abdominal discomfort, loose stools, and nausea; these symptoms usually disappeared within 3 months of treatment. Five patients discontinued octreotide because of adverse events. Of 102 patients with normal baseline ultrasound examinations of the gallbladder, 24 patients (23.5%) developed gallstones (usually during the first year of treatment), and 21 patients developed sludge alone. Gallstone formation was not related to the dose of octreotide. Most patients with cholelithiasis were asymptomatic, and none developed cholecystitis. These observations suggest that octreotide is a valuable long term medical treatment for acromegaly." @default.
• W2040996502 created "2016-06-24" @default.
• W2040996502 creator A5028097329 @default.
• W2040996502 creator A5034090492 @default.
• W2040996502 creator A5044371501 @default.
• W2040996502 creator A5046671975 @default.
• W2040996502 creator A5057382848 @default.
• W2040996502 creator A5060451560 @default.
• W2040996502 creator A5066985276 @default.
• W2040996502 creator A5069011201 @default.
• W2040996502 creator A5072466732 @default.
• W2040996502 creator A5086295199 @default.
• W2040996502 date "1995-09-01" @default.
• W2040996502 modified "2023-10-14" @default.
• W2040996502 title "Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study." @default.
• W2040996502 cites W1968914256 @default.
• W2040996502 cites W1970226357 @default.
• W2040996502 cites W1970252755 @default.
• W2040996502 cites W1972650975 @default.
• W2040996502 cites W1974172715 @default.
• W2040996502 cites W1975789485 @default.
• W2040996502 cites W1986534518 @default.
• W2040996502 cites W1988739357 @default.
• W2040996502 cites W1989673315 @default.
• W2040996502 cites W1991818495 @default.
• W2040996502 cites W1992000752 @default.
• W2040996502 cites W1994166680 @default.
• W2040996502 cites W1994899468 @default.
• W2040996502 cites W1995600453 @default.
• W2040996502 cites W1999063072 @default.
• W2040996502 cites W2000280678 @default.
• W2040996502 cites W2003130090 @default.
• W2040996502 cites W2004700740 @default.
• W2040996502 cites W2005614064 @default.
• W2040996502 cites W2006611896 @default.
• W2040996502 cites W2010563165 @default.
• W2040996502 cites W2010772266 @default.
• W2040996502 cites W2015421654 @default.
• W2040996502 cites W2017602672 @default.
• W2040996502 cites W2021453735 @default.
• W2040996502 cites W2021570880 @default.
• W2040996502 cites W2028928647 @default.
• W2040996502 cites W2030579930 @default.
• W2040996502 cites W2035865302 @default.
• W2040996502 cites W2036600263 @default.
• W2040996502 cites W2045287329 @default.
• W2040996502 cites W2053768683 @default.
• W2040996502 cites W2055305383 @default.
• W2040996502 cites W2057715521 @default.
• W2040996502 cites W2062952516 @default.
• W2040996502 cites W2075887192 @default.
• W2040996502 cites W2079611509 @default.
• W2040996502 cites W2083098067 @default.
• W2040996502 cites W2086985095 @default.
• W2040996502 cites W2088040716 @default.
• W2040996502 cites W2090065340 @default.
• W2040996502 cites W2091019371 @default.
• W2040996502 cites W2095480306 @default.
• W2040996502 cites W2131455589 @default.
• W2040996502 cites W2131555068 @default.
• W2040996502 cites W2132860204 @default.
• W2040996502 cites W2135371093 @default.
• W2040996502 cites W2145493248 @default.
• W2040996502 cites W2145509053 @default.
• W2040996502 cites W2152997319 @default.
• W2040996502 cites W2155174707 @default.
• W2040996502 cites W2267726834 @default.
• W2040996502 cites W2289711113 @default.
• W2040996502 cites W2339145711 @default.
• W2040996502 cites W2399628839 @default.
• W2040996502 cites W2417400529 @default.
• W2040996502 cites W2419549064 @default.
• W2040996502 doi "https://doi.org/10.1210/jcem.80.9.7673422" @default.
• W2040996502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7673422" @default.
• W2040996502 hasPublicationYear "1995" @default.
• W2040996502 type Work @default.
• W2040996502 sameAs 2040996502 @default.
• W2040996502 citedByCount "126" @default.
• W2040996502 countsByYear W20409965022012 @default.
• W2040996502 countsByYear W20409965022013 @default.
• W2040996502 countsByYear W20409965022014 @default.
• W2040996502 countsByYear W20409965022015 @default.
• W2040996502 countsByYear W20409965022018 @default.
• W2040996502 countsByYear W20409965022019 @default.
• W2040996502 countsByYear W20409965022020 @default.
• W2040996502 countsByYear W20409965022021 @default.
• W2040996502 countsByYear W20409965022022 @default.
• W2040996502 crossrefType "journal-article" @default.
• W2040996502 hasAuthorship W2040996502A5028097329 @default.
• W2040996502 hasAuthorship W2040996502A5034090492 @default.
• W2040996502 hasAuthorship W2040996502A5044371501 @default.
• W2040996502 hasAuthorship W2040996502A5046671975 @default.
• W2040996502 hasAuthorship W2040996502A5057382848 @default.
• W2040996502 hasAuthorship W2040996502A5060451560 @default.
• W2040996502 hasAuthorship W2040996502A5066985276 @default.
• W2040996502 hasAuthorship W2040996502A5069011201 @default.
• W2040996502 hasAuthorship W2040996502A5072466732 @default.
• W2040996502 hasAuthorship W2040996502A5086295199 @default.

• next